17-Iodine-123 iodoheptadecanoic acid for metabolic liver studies in humans.
(17-123I)-Iodoheptadecanoic acid ([123I]HA) was used for dynamic planar scintigraphy of the liver in normal individuals (control I), in patients without liver disease but with elevated serum cholesterol and/or triglycerides (control II), and in patient groups with alcohol-induced fatty liver (PG I), fatty liver not due to alcohol (PG II), alcohol-induced liver cirrhosis (PG III), or liver cirrhosis of the posthepatitic type (PG IV). Tracer uptake and elimination time were assayed in different liver regions; mean elimination time was expressed for total liver. In control I, tracer uptake was homogeneous, and mean elimination time was 20.7 +/- 5.3 min without significant local variations. In control II, tracer uptake was reduced but homogeneous and mean elimination time was 59.4 +/- 35.8 min with some local variations. In PG I, uptake was reduced and inhomogeneous and elimination time was the same as in control I, irrespective of cholesterol and triglyceride values. In PG II, uptake was the same as in PG I but mean elimination time was 48 +/- 8.1 min with some local variations. In PG III, uptake was extremely reduced and spotty and elimination time correlated with the severity of disease from 19 to 881 min in different liver regions.
D005227:Fatty Acids; D005234:Fatty Liver / Q000000981:diagnostic imaging / Q000378:metabolism; D005235:Fatty Liver, Alcoholic / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes; D008099:Liver / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000000981:diagnostic imaging / Q000378:metabolism; D008104:Liver Cirrhosis, Alcoholic / Q000000981:diagnostic imaging / Q000378:metabolism; D008107:Liver Diseases / Q000000981:diagnostic imaging* / Q000378:metabolism; D011877:Radionuclide Imaging
D005227:Fatty Acids; D007457:Iodine Radioisotopes; C027252:17-iodoheptadecanoic acid